



- 1001 Incidence of Pap Test Abnormalities Within 3 Years of a Normal Pap Test United States, 1991–1998
- 1004 Coccidioidomycosis in Travelers Returning From Mexico Pennsylvania, 2000
- 1006 Influenza Activity United States and Worldwide, April–October 2000
   1009 Notice to Readers

# Incidence of Pap Test Abnormalities Within 3 Years of a Normal Pap Test — United States, 1991–1998

Declines in cervical cancer incidence and mortality reported in the United States since the 1950s have been attributed to early detection and treatment of precancerous and cancerous lesions through the use of the Papanicolaou (Pap) test (1). More than 50 million Pap tests are performed each year (2); however, guidelines about the frequency of testing in women with a history of normal test results are inconsistent (3-5). To determine the incidence of cervical cytologic abnormalities following a normal Pap test, 1991–1998 data from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) were analyzed for this report (6). The findings indicated that within 3 years of a normal Pap test result, severe cytologic abnormalities were uncommon, and incidence rates were similar among women screened 1, 2, and 3 years following a normal Pap test.

For each woman, CDC received a report that included demographic characteristics, Pap test results, diagnostic procedures, and histopathologic results (6,7). To be eligible for the analysis, women were required to have had a first NBCCEDP Pap test reported as normal during 1991–1998, and at least one subsequent Pap test performed within the following 9–36 months. Of 620,063 women tested during 1991–1998, 128,805 (20.8%) met the criteria for eligibility. Results of Pap tests were reported using Bethesda System categories: normal; infection, inflammation, or reactive changes; atypical squamous cells of undetermined significance (ASCUS); low-grade squamous intraepithelial lesion (LSIL); high-grade squamous intraepithelial lesion (HSIL); "suggestive of squamous cell carcinoma"; and "other" (e.g., glandular atypia and atypical endocervical glands).

Incidence rates of Pap test interpretations were calculated by dividing the number of women with each test result by the number of women retested within each age group (<30, 30–49, 50–64, and ≥65 years) and time interval (9–12, 13–24, and 25–36 months). Incidence rates were age-adjusted using the age distribution of the 1996 NBCCEDP population. Ordinary least-squared regression was used to evaluate the trend of increasing time between the first Pap test on the age-adjusted incidence of ASCUS, LSIL, HSIL, and suggestive of squamous cell carcinoma.

The average age of women included in the analysis was 48.9 years (range: 12–96 years); 73,631 (57.0%) were non-Hispanic whites, 22,672 (17.6%) were Hispanics, 17,314 (13.4%) were non-Hispanic blacks, 10,983 (8.5%) were American Indians/Alaska natives, 3070 (2.4%) were Asians/Pacific Islanders, and 1135 (0.9%) were categorized as "other" or "unknown." The mean time between the first and second test was 15.7

## Pap Test Abnormalities — Continued

months. Approximately 121,576 (94.4%) of the 128,805 second test results were interpreted as normal or infection, inflammation, or reactive changes. The incidence rate of the second test results interpreted as HSIL and suggestive of squamous cell carcinomas was 66 per 10,000 women aged <30 years, 22 per 10,000 women aged 30–49 years, 15 per 10,000 women aged 50–64, and 10 per 10,000 women aged  $\geq$ 65 years (trend test, p<0.001). Overall, as age increased, the incidence of ASCUS and LSIL also decreased (trend test, p<0.001, each category).

The age-adjusted incidence of results interpreted as LSIL increased over time (trend test, p=0.01) (Table 1). The incidence of ASCUS, the most common cytologic abnormality, did not change significantly over time (p=0.36). The differences in the age-adjusted incidence of HSIL and suggestive of squamous cell carcinoma for the time intervals also were not significant (p=0.42).

Reported by: GF Sawaya, MD, K Kerlikowske, MD, G Gildengorin, PhD, AE Washington, MD, Univ of California, San Francisco. Div of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion; CDC.

**Editorial Note:** The U.S. Preventive Services Task Force recommends Pap test screening at least every 3 years until age 65 years (5). The American Cancer Society guidelines suggest that screening less frequent than annually may be adequate for Pap testing in women with a history of 3 negative annual Pap tests (3), and the American College of Obstetricians and Gynecologists recommends annual Pap tests for most women (4).

The difference in screening annually, biennually, or triennially is substantial in the number of tests performed and in the public health implications. In this analysis, women screened 1, 2, and 3 years after a normal Pap test had similar risk for developing HSIL and suggestive of squamous cell carcinoma. Other studies have indicated clinically insignificant additional protection in testing yearly compared with triennially (8). However, low-grade abnormal Pap results (e.g., ASCUS and LSIL) constituted >95% of the cytologic abnormalities after the first normal results. The clinical significance of these abnormalities is unclear. Women who were screened annually rather than less frequently might have worse health outcomes if low-grade results of undetermined clinical importance lead to further testing and unnecessary patient morbidity and anxiety (9,10).

		Cytologic interpretation of Pap te	st
No. months since normal Pap	ASCUS⁺	LSIL <sup>s</sup>	HSIL <sup>¶</sup> and suggestive of squamous cell carcinoma
9–12	377	107	25
13–24	373	125	29
25–36	415	141	33
P for trend	0.36	0.01	0.42

TABLE 1. Age-adjusted incidence rate\* of cytologic abnormalities, by time fromnormal Papanicolaou (Pap) test — National Breast and Cervical Cancer EarlyDetection Program, United States, 1991–1998

\* Per 10,000 women.

<sup>†</sup> Atypical squamous cells of undetermined significance.

<sup>§</sup> Low-grade squamous intraepithelial lesion.

<sup>¶</sup> High-grade squamous intraepithelial lesion.

#### Vol. 49 / No. 44

#### MMWR

## Pap Test Abnormalities — Continued

The findings in this report are subject to at least four limitations. First, the database used was intended for descriptive statistics and not for hypothesis testing; data were limited to a few variables. Second, NBCCEDP serves low-income and uninsured women; results may not be generalizable to other groups. However, low-income and uninsured women usually are at greater risk for developing cervical neoplasia than women with higher incomes; therefore, higher-income women should be less likely to exhibit higher rates during the 3-year interval examined in this study. Third, women may have received Pap testing outside the program during the time between the first and subsequent Pap tests; however, this probably occurred in only a few women. Finally, women who frequently get screened, specifically within 1 year after Pap test, might be low-risk women concerned about their health or high-risk women with histories of abnormal Pap tests who have been told to get annual tests. Other risks for cervical cancer in these women and whether these risks affected the findings in this study are unknown. NBCCEDP receives data from many cytopathology laboratories and clinical settings. The findings in this study may better represent actual clinical settings than the findings in a controlled trial.

CDC is working with state health departments to use this information as a basis for cost-effective strategies to reach women who have not received screening services for cervical disease. CDC will assist NBCCEDP in assessing program-provider practices, modifying patient recall systems, and developing professional and public education strategies to improve patient-provider decision making. Further research is needed to clarify the benefit and harm related to frequency of subsequent Pap testing in women with normal results.

## References

- 1. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med 1996;334:1030-8.
- 2. Richart RM. Screening: the next century. Cancer 1995;76:1919-27.
- 3. American Cancer Society: Guidelines for the cancer related checkup. Atlanta, Georgia: American Cancer Society, 1998.
- American College of Obstetricians and Gynecologists routine cancer screening: committee opinion 185. Washington, DC: American College of Obstetricians and Gynecologists, 1997.
- 5. U.S. Preventive Services Task Force. Guide to clinical preventive services: an assessment of the effectiveness of 169 interventions. Report of the U.S. Preventive Services Task Force, Baltimore, Maryland: Williams and Wilkins, 1996.
- 6. Sawaya GF, Kerlikowske K, Lee NC, Gildengorin G, Washington AE. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol 2000;96:219–23.
- Lawson HW, Lee NC, Thames SF, Henson R, Miller DS. Cervical cancer screening among low-income women: results of a national survey program, 1991–1995. Obstet Gynecol 1998;92:745–52.
- International Agency for Research on Cancer Working Group on Evaluation of Cervical Cancer Screening Programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. BMJ 1986;293:659–64.
- 9. Jones MH, Singer A, Jenkins D. The mildly abnormal cervical smear: patient anxiety and choice of management. J Soc Med 1996;89:257–60.
- 10. Bell S, Porter M, Kitchener H, Fraser C, Fisher P, Mann E. Psychological response to cervical screening Prev Med 1995;24:610–6.

## Coccidioidomycosis in Travelers Returning From Mexico — Pennsylvania, 2000


Coccidioidomycosis (CM), a fungal disease caused by *Coccidioides immitis*, is endemic in the southwestern United States and parts of Central and South America. The disease is acquired by inhaling the arthroconidia of *C. immitis* present in the soil. Outbreaks of CM occur when susceptible persons are exposed to airborne arthroconidia from dust storms, natural disasters, and earth excavation (1,2). Persons who travel to areas where the disease is endemic may become infected and develop symptoms after returning home (3,4). This report describes an outbreak of CM among travelers returning to Pennsylvania from a trip to Mexico.


On January 24, 2000, 35 church members from two cities in Pennsylvania traveled to Hermosillo, Mexico, where they stayed 1 week to construct a church. Within 2 weeks of returning home, 27 travelers complained of influenza-like symptoms, and initial testing of acute serum specimens at CDC revealed antibodies to *C. immitis* for one traveler.

To determine the extent of the outbreak and to identify potential risk factors for developing CM, the Pennsylvania Department of Health and CDC conducted a cohort study and collected acute and convalescent-phase serum samples from consenting church members. Serum specimens were tested for antibodies to *C. immitis* by immunodiffusion and complement fixation at CDC and the University of California-Davis. A case was defined as a positive serologic test for coccidioidal antibodies by 1) detection of coccidioidal immunoglobulin M by immunodiffusion, enzyme immunoassay (EIA) latex agglutination, or tube precipitin, or 2) detection of rising titer of coccidioidal immunoglobulin G by immunodiffusion, EIA, or complement fixation in a church member from Pennsylvania who had traveled to Hermosillo during January 24–February 2, 2000. All participants completed a standardized questionnaire about medical history, activities while in Mexico, and environmental exposures.

A questionnaire and at least one serum sample was obtained for 30 (86%) of the 35 church members. Twenty-nine (97%) were men; median age was 45 years (range: 18–62 years). Twenty-three (77%) persons reported becoming ill either in Mexico or within 3 weeks of returning home. Based on serologic testing, eight (27%) persons met the case definition for CM, seven of whom were symptomatic (Figure 1). The incubation period ranged from 8 days after arriving in Mexico to 15 days after returning to Pennsylvania from Mexico. The most common symptoms were fatigue, fever, arthralgias, and myalgias (71% in each). Three had a rash, and four had a cough. The median duration of symptoms was 7 days (range: two–35). Eighteen (78%) of 23 ill persons sought care from at least one health-care provider. Twelve (67%) persons had chest radiographs performed as part of their evaluation; six were abnormal. Eleven of these 18 persons were prescribed medications for their symptoms; six were prescribed either fluconazole or itraconazole once it was known that a CM outbreak had occurred. One person required hospitalization in an intensive care unit for 1 day. Of 23 ill persons, 11 (48%) missed work or school for an average of 5.5 days.

No activities or other conditions were associated substantially with infection or symptomatic disease. However, 22 (73%) church members reported working in extremely dusty conditions. Nineteen (63%) persons reported histories of previous travel to Hermosillo or other areas where *C. immitis* is endemic; but only one case-patient reported history of such travel. Coccidioidomycosis — Continued





\* N=23. Data is missing on onset of symptoms for three persons.

Reported by: J Zurlo, MD, T Crook, MD, W Green, MD, J Adams, MD, Hershey Medical Center, Hershey; C Freer, MD, Hanover Hospital, Hanover; J Ratner, MD, Center Community Hospital, State College; N M'ikanatha, DrPH, J Rankin, DVM, L Stetson, MPH, S Yeager, Pennsylvania Dept of Health. D Pappagianis, MD, Univ of California-Davis, Davis. Mycotic Diseases Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; and EIS officers, CDC.

**Editorial Note**: The outbreak in this report and a similar outbreak in a group from Washington (*3*) underscore the need for increased awareness about CM and its risk factors among susceptible persons visiting areas where the disease is endemic, especially among persons who engage in construction work or other activities in dusty environments. Travel to these areas has become more common because of various missionary and other travel activities to Mexico and relocation of persons from areas in the Northwest and Midwest to the southwestern United States (*3–5*). In addition, CM has increased among U.S. travelers to areas where CM is endemic, especially among the elderly (*6*). Persons with certain underlying illnesses (e.g., human immunodeficiency virus [HIV] and elderly with chronic medical conditions) who travel to areas where CM is endemic areas the CM is endemic are at increased risk for severe pulmonary or disseminated CM (*7,8*).

Approximately 40% of persons infected with *C. immitis* develop symptomatic disease. Most (85%) symptomatic persons present with a mild, influenza-like illness; 8% may develop severe pulmonary disease requiring hospitalization, and 7% develop disseminated, extrapulmonary disease (7). Risk factors for disseminated disease include black or Asian race, pregnancy, and immunocompromising conditions (e.g., acquired immunodeficiency syndrome); risk factors for severe pulmonary disease include diabetes, smoking, and older age (7).

## Coccidioidomycosis — Continued

Although avoiding activities that generate dust or using a mask during these activities is advisable, these measures do not provide complete protection. A potential strategy for adequate prevention is vaccine development because natural infection with *C. immitis* provides life-long immunity (9). However, until a vaccine becomes available, organizations that conduct trips to areas where CM is endemic should inform their travelers about the risks for CM. Health-care providers should consider CM in travelers returning from areas where the disease is endemic and who present with an influenza-like illness. Early diagnosis of CM will result in better use of medical resources and will help alleviate patient concerns and may prevent more severe disease (7).

### References

- 1. Pappagianis D, Einstein H. Tempest from Tehachapi takes toll on *Coccidioides* conveyed aloft and afar. West J Med 1978;129:527–30.
- Schneider E, Hajjeh RA, Spiegel RA, et al. A coccidioidomycosis outbreak following the Northridge, California, earthquake. JAMA 1997;277:904–8.
- Cairns L, Blythe D, Kao A, et al. Outbreak of coccidioidomycosis in Washington state residents returning from Mexico. Clin Infect Dis 2000;30:61–4.
- Chaturvedi V, Ramani R, Gromadzke S, et al. Coccidioidomycosis in New York State. Emerg Infect Dis 2000;6:25–9.
- Ampel NM, Mosley DG, England B, et al. Coccidioidomycosis in Arizona, increase in incidence from 1990 to 1995. Clin Infect Dis 1998;27:1523–30.
- 6. CDC. Update: coccidioidomycosis—California, 1991-1993. MMWR 1994;4:421-3.
- Rosenstein NE, Emery KW, Werner B, et al. Risk factors for severe pulmonary and disseminated coccidiodomycosis, Kern County, CA 1995–1996. Clin Infect Dis (in press).
- 8. Leake JAD, Mosley DG, England B, et al. Risk factors for acute symptomatic coccidioidomycosis among elderly persons in Arizona, 1996–1997. J Infect Dis 2000;181:1435–40.
- 9. Deepe GS Jr. Prospects for the development of fungal vaccines. Clin Microb Rev 1997;10:585-96.

## Influenza Activity — United States and Worldwide, April–October 2000

During October 1999–May 2000, influenza A(H3N2), A(H1N1), and B viruses were identified in the Northern Hemisphere. Influenza A(H3N2) predominated, but the number of influenza A(H1N1) viruses increased toward the end of the influenza season in the Northern Hemisphere. Since April, influenza A viruses have predominated in the Southern Hemisphere and tropical regions, but influenza B viruses also have been identified. This report summarizes influenza activity in the United States and worldwide from April 2000 through October 2000.

## **United States**

The WHO Collaborating Center for Reference and Research at CDC conducts active national surveillance for influenza from October through May (1). Although formal weekly reporting is discontinued during summer months, WHO collaborating laboratories can report influenza viruses during the summer to CDC and submit these viruses for antigenic characterization. Since March, influenza A(H1N1) viruses have been the most frequently isolated influenza viruses in the United States. Influenza A(H1N1) viruses were identified each month from April through July and were isolated from an outbreak in July among children and staff at a summer camp in Texas. Influenza A(H1N1) viruses were identified during October in California, Florida, and Texas. Influenza A(H3N2) viruses were isolated from sporadic cases during April, from one immunocompromised

### Influenza Activity — Continued

patient in June, from one imported case in an immune suppressed person in August in Massachusetts, and from three cases in October (one each in California, Hawaii, and Kentucky). Additional influenza A viruses (unsubtyped) were identified in California and Texas during September and in Utah in October. Influenza B viruses were identified each month through May. During August–October, influenza B viruses were identified in Alaska, California, Nevada, Oklahoma, and Washington.

## Worldwide

From April through October, influenza A(H1N1), A(H3N2), and B viruses were reported from Asia; influenza A viruses were reported more frequently than influenza B viruses. In Africa, influenza A(H1N1) viruses were reported more frequently than A(H3N2) viruses from April through August, but all subtyped influenza A viruses reported during September were A(H3N2). In Canada, both influenza A and B viruses were reported each month from April through July; most of the viruses reported during June–July were influenza type B. During September–October, influenza A and B viruses were reported in Canada, and influenza A viruses were reported from Mexico. Influenza type A and B viruses also were isolated in Europe during September–October. In South America, influenza A(H1N1) viruses predominated, but influenza A(H3N2) and B viruses were isolated. In Oceania, influenza type A viruses were more commonly isolated than influenza type B; both A(H3N2) and A(H1N1) subtypes circulated.

## Characterization of influenza virus isolates

The WHO Collaborating Center for Reference and Research on Influenza at CDC analyzes isolates received from laboratories worldwide. Of the 205 influenza A(H1N1) isolates that were collected and antigenically characterized during April–October, 173 (84%) were similar to A/New Caledonia/20/99, the H1N1 component of the 2000–01 influenza vaccine, 31 (15%) were similar to A/Bayern/07/95, and one (0.5%) showed reduced titers with A/New Caledonia/20/99 antisera. Although A/Bayern-like viruses are antigenically distinct from the A/New Caledonia-like viruses, the A/New Caledonia/20/99 vaccine strain produces high titers of antibody that cross-react with A/Bayern/07/95-like viruses. Of the 205 antigenically characterized H1N1 viruses, 136 were from South or Central America, 42 from the United States, 18 from Asia, seven from Australia, New Zealand, and New Caledonia, and two from Africa.

Of the 65 influenza A(H3N2) viruses antigenically characterized, 60 (92%) were well inhibited by antiserum to the recommended vaccine strain, A/Moscow/10/99. Thirty-four of the antigenically characterized H3N2 viruses were from South America, 17 from Asia, five from Australia, New Zealand, and New Caledonia, four from the United States, two each from Canada and Africa, and one from Europe.

Of the 53 antigenically characterized influenza B viruses, 52 (98%) were antigenically similar to the recommended vaccine strain, B/Beijing/184/93. Seventeen of the influenza B viruses were from Asia, 15 from the United States, 10 from South America, nine from Australia, New Zealand, and New Caledonia, and one each from Africa and Europe.

Reported by: World Health Organization National Influenza Centers, Communicable Diseases, Surveillance and Response, World Health Organization, Geneva, Switzerland. A Hay, PhD, WHO Collaborating Center for Reference and Research on Influenza, National Institute for Medical Research, London, England. I Gust, MD, A Hampson, WHO Collaborating Center for Reference and Research on Influenza, Parkville, Australia. M Tashiro, MD, WHO Collaborating Center for Reference and Research on Influenza, National Institute of Infectious Diseases, Tokyo, Japan. S Lea, MD, C Burgoon, DVM, Waco-McLennan County Health Dept, Waco; M Gaglani, MD, G Herschler, Scott & White Hospital, Temple; D Haught, MSN, Baylor College of

#### Influenza Activity — Continued

Medicine, Austin; L Dobin, D Berkman, Greene Family Camp, McLennan County; N Pascoe, J Morgan, MD, MA Patterson, D Romnes, D Bergmire-Sweat, MPH, Texas Dept of Health. WHO collaborating laboratories. WHO Collaborating Center for Reference and Research on Influenza, Influenza Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC.

**Editorial Note**: Influenza A(H1N1), A(H3N2), and B viruses circulated in the Southern Hemisphere during the winter season. Influenza activity in the Southern Hemisphere influenza seasons when a larger proportion of the circulating influenza viruses were A(H3N2) viruses. The identification of sporadic influenza cases and isolated influenza outbreaks during the summer and fall months is not unusual. Recent isolates from the Northern Hemisphere have been predominantly influenza A(H1N1) and influenza B viruses. The type(s)/subtype(s) of influenza virus that will circulate, the timing of onset and peaking, and the severity of the upcoming season in the Northern Hemisphere cannot be predicted. Persons at increased risk for influenza-related complications should receive annual influenza vaccination to reduce their chances for influenza infection and the severity of the illness should they become infected (2-4).

In February of each year, the World Health Organization (WHO) recommends influenza virus strains for inclusion in the following season's Northern Hemisphere influenza vaccine. The regulatory authorities in each country then determine the actual viruses to be used for vaccine production. Frequently, the regulatory authorities in a country will substitute an antigenically equivalent virus for one or more of the WHO recommended viruses because of better growth or processing properties. In the United States, the Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee is responsible for the selection of vaccine strains to be used by U.S. vaccine manufacturers. For the 2000–01 influenza season, WHO has recommended A/New Caledonia/20/ 99-like (H1N1), A/Moscow/10/99-like (H3N2), and B/Beijing/184/93-like viruses for inclusion in the Northern Hemisphere influenza vaccine (*5*). U.S. vaccine manufacturers used the antigenically equivalent stains A/Panama/2007/99 (H3N2) for the A/Moscow/10/99like strain and B/Yamanashi/166/98 for the B/Beijing/184/93-like strain. Most viruses isolated since April, both in the United States and worldwide, are well matched to the current vaccine strains.

CDC collects and reports U.S. influenza surveillance data during October–May. This information is updated weekly and is available through the CDC voice information system, telephone (888) 232-3228, or the fax information system, telephone (888) 232-3299, by requesting document number 361100, or on the Influenza Branch World-Wide Web site at http://www.cdc.gov/ncidod/diseases/flu/weekly.htm.

## References

- 1. CDC. Influenza activity—United States, 1999–2000 season. MMWR 1999;48:1039–42.
- CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(no. RR-3).
- CDC. Delayed supply of influenza vaccine and adjunct ACIP influenza vaccine recommendations for the 2000-01 influenza season. MMWR 2000:49;619-22.
- CDC. Updated recommendations from the Advisory Committee on Immunization Practices in response to delays in supply of influenza vaccine for the 2000–01 season. MMWR 2000:49;888–92.
- 5. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2000–01 season. Wkly Epidemiol Rec 2000;75:61–5.

## Notice to Readers

## **HIV Draft Documents Available for Comment**

CDC announces the availability of two draft documents for public comment: "Revised Guidelines for HIV Counseling, Testing, and Referral" and "Revised Public Health Service Recommendations for HIV Screening of Pregnant Women."


Comments must be submitted in writing and posted or e-mailed by November 30, 2000. Comments should be mailed to the Technical Information and Communications Branch, Mailstop E-49, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, CDC, 8 Corporate Square, Atlanta, GA 30329-2013 (overnight shipping: TICB-CDC, E-49); faxed, (404) 639-2007; or e-mailed, hivmail@cdc.gov.

Readers should use specific paragraph and page numbers when commenting on each separate document and submit one copy of comments.

Copies of the drafts can be obtained from CDC National Prevention Information Network, P.O. Box 6003, Rockville, MD 20849-6003; telephone, (800) 458-5231; or from the Division of HIV/AIDS Prevention World-Wide Web site, http://www.cdc.gov/hiv.

## Erratum: Vol. 49, No. SS-10

In the CDC Surveillance Summaries article titled "Youth Tobacco Surveillance — United States, 1998–1999," Table 5 and Table 21 contain some incorrect data for New Jersey. In Table 5 on page 49, in the column of data for "Any tobacco," the correct New Jersey numbers are 18.9 ( $\pm$ 2.1) for middle school students and 38.9 ( $\pm$ 2.4) for high school students. In Table 21 on page 65, in the column of data for "Think persons can get addicted to cigarettes," under "Never Smokers," the correct New Jersey numbers are 95.7 ( $\pm$ 0.8) for middle school students and 95.7 ( $\pm$ 1.6) for high school students; under "Current smokers," the correct New Jersey numbers are 87.2 ( $\pm$ 2.9) for middle school students and 90.1 ( $\pm$ 2.0) for high school students.



## FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending November 4, 2000, with historical data

\* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

		Cum. 2000		Cum. 2000
Anthrax		-	Poliomyelitis, paralytic	-
Brucellosis*		56	Psittacosis*	8
Cholera		2	Q fever*	18
Cyclosporiasis	*	37	Rabies, human	1
Diphtheria		1	Rocky Mountain spotted fever (RMSF)	385
Ehrlichiosis:	human granulocytic (HGE)*	149	Rubella, congenital syndrome	6
	human monocytic (HME)*	90	Streptococcal disease, invasive, group A	2,373
Encephalitis:	California serogroup viral*	98	Streptococcal toxic-shock syndrome*	64
•	eastern equine <sup>×</sup>	1	Syphilis, congenital <sup>¶</sup>	173
	St. Louis <sup>*</sup>	2	Tetanus	21
	western equine*	-	Toxic-shock syndrome	119
Hansen diseas	se (leprosy)*	55	Trichinosis	14
Hantavirus pu	Imonary syndrome* <sup>†</sup>	27	Tularemia*	109
Hemolytic ure	mic syndrome, postdiarrheal*	159	Typhoid fever	276
HIV infection,	pediatric* <sup>§</sup>	190	Yellow fever	-
Plague	•	5		

## TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending November 4, 2000 (44th Week)

-: No reported cases. \*Not notifiable in all states.

<sup>1</sup>Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID). <sup>3</sup>Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last update October 29, 2000.

<sup>¶</sup>Updated from reports to the Division of STD Prevention, NCHSTP.

			011	audia†	Omente	a avializa - ta			coli O157:H	
	Cum.	DS Cum.	Chlan Cum.	nydia⁺ Cum.	Cum.	poridiosis Cum.	NET Cum.	Cum.	PH Cum.	LIS Cum.
Reporting Area	2000 <sup>§</sup> 33,120	<b>1999</b> 37,258	2000 549,347	<b>1999</b> 555,956	2000 2,286	<b>1999</b> 2,298	<b>2000</b> 3,896	<b>1999</b> 3,241	2000 2,816	<b>1999</b> 2,467
NEW ENGLAND	1,699	1,884	17,377	17,929	2,200 99	164	353	376	340	346
Maine N.H.	28 29	68 40	1,239 872	835 827	20 21	25 17	27 32	35 31	26 29	- 31
Vt. Mass.	32 1,061	15 1,211	455 7,341	414 7,625	26 29	34 63	33 154	32 164	33 156	20 176
R.I.	84	90	2,104	1,974	3	4	18	26	16	26
Conn. MID. ATLANTIC	465 7,189	460 9,653	5,366 46,712	6,254 56,047	- 159	21 497	89 357	88 292	80 233	93 114
Upstate N.Y.	694	1,147	Ń	Ń	111	140	262	224	57	-
N.Y. City N.J.	3,765 1,461	5,101 1,732	21,447 7,016	23,125 10,513	10 9	219 43	10 85	17 51	10 106	17 58
Pa.	1,269	1,673	18,249	22,409	29	95	N	Ν	60	39
E.N. CENTRAL Ohio	3,190 489	2,534 421	90,466 22,498	93,194 25,226	737 248	587 58	873 244	888 203	520 197	489 203
Ind. III.	324 1,597	282 1,202	10,735 23,888	10,340 27,653	57 7	38 82	120 175	86 485	77	63 81
Mich.	604	502	22,111	18,545	90	46	127	114	102	78
Wis. W.N. CENTRAL	176 767	127 839	11,234 30,379	11,430 31,786	335 348	363 184	207 628	N 481	144 529	64 508
Minn.	153	158	6,129	6,399	132 74	68 53	198 176	156	166 139	174
lowa Mo.	75 349	70 408	4,252 9,728	3,879 11,293	30	22	101	103 40	90	75 59
N. Dak. S. Dak.	2 7	6 13	577 1,558	772 1,311	15 15	18 7	15 53	16 44	18 55	16 59
Nebr. Kans.	65 116	58 126	3,069 5,066	2,942 5,190	73 9	14 2	59 26	93 29	45 16	111 14
S. ATLANTIC	9,203	10,213	108,997	118,858	419	335	333	293	256	174
Del. Md.	183 1,131	146 1,240	2,418 11,533	2,350 11,147	5 10	- 17	1 29	6 38	1 1	3 4
D.C.	695	493	2,753	Ń	15	7	1	1	U	U
Va. W. Va.	598 56	684 61	13,706 1,442	12,466 1,560	17 3	21 3	65 14	68 13	55 12	55 8
N.C. S.C.	609 703	691 842	18,854 8,449	18,914 15,934	22	22	81 21	64 18	64 14	51 14
Ga. Fla.	1,050 4,178	1,466 4,590	21,901 27,941	29,214 27,273	151 196	121 144	38 83	28 57	36 73	1 38
E.S. CENTRAL	1,644	1,661	41,670	39,237	44	31	121	127	94	101
Ky. Tenn.	169 706	241 640	6,841 12,499	6,393 12,259	5 11	6 10	42 52	44 53	31 45	33 43
Ala.	420	418	13,029	10,741	15	10 11 4	9	22	9	21
Miss. W.S. CENTRAL	349 3,413	362 3,803	9,301 84,487	9,844 78,515	13 106	4 78	18 173	8 131	9 213	4 140
Ark.	159 606	156 743	4,977	5,217	11 10	1 23	55 9	14 13	30 44	13 14
La. Okla.	291	116	15,261 7,680	13,970 6,821	17	10	18	34	14	26
Tex.	2,357	2,788	56,569 21,570	52,507	68 162	44 90	91 206	70 204	125	87 221
MOUNTAIN Mont.	1,232 12	1,464 11	31,570 1,154	28,366 1,336	162 10	89 10	396 30	294 24	229	231
Idaho Wyo.	19 9	20 10	1,512 652	1,454 653	21 5	7 1	66 17	56 14	- 9	42 16
Cólo. N. Mex.	291 126	271 78	8,390 3,721	5,606 4,238	68 17	12 38	151 20	109 12	104 15	87 6
Ariz.	403	742	10,930	10,596	11	12 N	47	29	34	20 45
Utah Nev.	117 255	128 204	1,916 3,295	1,816 2,667	26 4	9	52 13	33 17	67 -	46 15
PACIFIC Wash.	4,783 445	5,207 303	97,689 10,661	92,024 10,108	212 N	333 N	662 208	359 141	402 173	364 167
Oreg.	146	185	4,233	5,255	16	88	148	66	110	68
Calif. Alaska	4,072 21	4,628 13	78,235 2,016	72,327 1,613	196 -	245	264 27	139 1	108 1	117 1
Hawaii	99	78	2,544	2,721	-	-	15	12	10	11
Guam P.R.	15 1,134	11 1,094	- 3,305	393 U	-	-	N 6	N 5	U U	U U
V.I. Amer. Samoa	31	35	U U	Ŭ U	U U	U U	Ŭ	Ŭ U	Ŭ	Ŭ
C.N.M.I.	-	-	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ

 TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending November 4, 2000, and November 6, 1999 (44th Week)

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands. \* Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS). <sup>†</sup> Chlamydia refers to genital infections caused by *C. trachomatis.* Totals reported to the Division of STD Prevention, NCHSTP. <sup>§</sup> Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update October 29, 2000.

	Gono	rrhea	Hepati Non-A,		Legione	llosis	Listeriosis		/me sease
Reporting Area	Cum. 2000§	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 2000	Cum. 1999
UNITED STATES	286,882	306,283	2,519	2,441	809	868	583	11,528	13,634
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	4,843 79 90 56 1,988 526 2,104	5,645 67 96 42 2,122 496 2,822	14 2 - 4 3 5 -	14 2 - 6 3 3 -	49 2 5 15 8 17	69 3 13 25 9 11	42 2 3 23 1 11	3,837 59 27 1,018 417 2,316	4,100 41 20 20 730 450 2,839
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	28,881 6,156 9,299 4,901 8,525	33,874 5,711 10,550 6,648 10,965	544 59 - 450 35	112 50 - 62	169 76 - 12 81	217 54 40 18 105	141 78 26 19 18	5,900 3,261 19 1,426 1,194	7,225 3,370 132 1,577 2,146
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	55,074 13,639 5,055 16,154 15,401 4,825	58,662 15,509 5,471 19,582 13,018 5,082	191 11 14 165	836 3 45 771 16	216 102 35 9 44 26	235 68 37 30 59 41	101 50 7 11 28 5	315 82 32 11 190	564 42 17 17 11 477
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak.	13,665 2,435 997 6,450 35 258 1 187	14,120 2,428 1,029 6,954 74 157 1,240	428 5 406 -	235 10 222 -	54 7 13 24 - 2	47 9 12 16 1 3	13 5 3 4 1	356 267 26 41 1	285 173 22 63 1
Nebr. Kans.	1,187 2,303	1,249 2,229	6 9	3	4 4	6	-	4 17	11 15
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	80,560 1,452 7,995 2,255 8,944 465 15,417 10,588 14,176 19,268	90,401 1,461 8,486 3,171 8,205 493 16,788 12,337 19,970 19,490	109 18 3 14 14 2 3 52	145 20 1 10 17 32 22 1 42	174 9 61 5 31 N 14 4 6 44	116 15 28 3 28 N 14 8 1 19	97 2 21 7 3 - 9 21 34	895 140 493 7 135 29 43 7 7 41	1,164 121 818 4 109 16 66 4 - 26
E.S. CENTRAL Ky. Tenn. Ala. Miss.	30,225 3,018 9,929 10,199 7,079	31,416 2,901 9,875 9,616 9,024	382 31 83 7 261	243 17 93 1 132	31 18 10 3	45 17 22 4 2	18 3 11 4	46 11 28 6 1	95 17 55 19 4
W.S. CENTRAL Ark. La. Okla. Tex.	44,549 2,689 11,247 3,436 27,177	45,091 2,837 11,247 3,372 27,635	406 9 291 8 98	475 26 277 15 157	16 - 6 3 7	27 1 5 3 18	15 1 - 6 8	37 4 3 - 30	54 4 9 7 34
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	8,620 39 69 41 2,535 827 3,618 186 1,305	8,223 47 73 26 2,117 842 3,836 182 1,100	284 4 3 210 21 13 18 2 13	174 5 7 56 29 28 35 6 8	40 1 5 2 14 1 8 9	40 - 2 11 1 6 14 6	29 - 1 6 2 12 4 4	29 - 3 9 11 - 3 3	14 - 3 3 1 - 2 2
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	20,465 1,918 607 17,331 283 326	18,851 1,786 766 15,651 262 386	161 29 27 103 - 2	207 17 16 174 -	60 17 N 43 -	72 17 N 53 1 1	127 5 5 114 - 3	113 9 11 91 2 N	133 10 12 111 N
Guam P.R. V.I. Amer. Samoa C.N.M.I.	574 U U U	43 288 U U U	- 1 U U U	1 - U U U	- 1 U U U	- U U U	- - - -	N U U U	N U U U

# TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending November 4, and November 6, 1999 (44th Week)

N: Not notifiable.

U: Unavailable. -: No reported cases.

		9 140 4011	501 4,20	vv, anu N		<b>6, 1999 (4</b> Salmor	ellosis*	<b>\</b> /
	Mala	aria	Rabie	s, Animal	NE	TSS		ILIS
Reporting Area	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
UNITED STATES	1,058	1,236	5,080	5,778	30,985	33,253	26,308	28,895
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	57 6 1 2 22 8 18	56 3 2 4 19 4 24	707 117 21 54 230 55 230	769 150 45 86 191 84 213	1,921 111 125 101 1,085 121 378	1,933 121 122 84 1,033 120 453	1,860 83 124 108 1,022 128 395	1,948 97 120 73 1,050 144 464
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	204 70 75 33 26	362 61 210 51 40	904 623 U 167 114	1,124 798 U 161 165	3,481 1,047 810 774 850	4,537 1,137 1,287 961 1,152	3,743 1,113 816 670 1,144	4,545 1,181 1,304 994 1,066
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	109 18 6 46 29 10	151 18 19 68 38 8	139 48 - 21 64 6	158 34 12 10 83 19	4,432 1,291 570 1,227 774 570	4,774 1,141 457 1,440 884 852	2,904 1,207 513 1 826 357	4,166 956 423 1,396 873 518
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	54 27 3 8 2 1 7 6	65 33 13 - - 1 5	478 80 71 49 107 81 2 88	658 99 140 29 129 164 4 93	2,103 495 322 616 55 87 196 332	1,988 507 223 657 40 85 173 303	2,172 572 289 794 67 93 91 266	2,147 643 204 776 57 110 148 209
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	292 5 100 15 48 4 33 2 22 63	298 1 86 17 63 2 26 15 21 67	2,099 47 353 - 497 106 504 142 306 144	1,887 50 349 - 497 98 392 132 204 165	7,057 101 729 57 882 145 972 655 1,300 2,216	7,523 143 755 70 1,130 1,130 1,155 561 1,255 2,302	4,742 126 673 U 753 135 916 482 1,453 204	5,731 137 791 U 925 139 1,187 453 1,482 617
E.S. CENTRAL Ky. Tenn. Ala. Miss.	42 17 11 13 1	23 7 8 7 1	185 19 94 72	227 34 81 111 1	2,046 334 555 588 569	1,869 359 506 535 469	1,479 225 644 521 89	1,307 250 532 436 89
W.S. CENTRAL Ark. La. Okla. Tex.	18 3 7 8	15 3 10 2	71 20 51	418 14 - 84 320	2,763 618 248 344 1,553	3,238 588 667 407 1,576	3,643 508 612 233 2,290	2,445 207 524 313 1,401
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	45 1 22 - 7 6 6	40 4 3 1 17 2 6 4 3	228 62 9 47 - 19 72 10 9	195 55 42 1 9 72 8 8	2,467 82 104 55 646 201 693 450 236	2,643 67 99 64 653 341 778 465 176	1,882 - 37 606 167 641 431	2,300 1 95 638 265 713 483 49
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	237 28 37 161 - 11	226 24 19 170 1 12	269 - 7 240 22 -	342 4 331 7	4,715 507 277 3,666 56 209	4,748 585 380 3,430 51 302	3,883 547 331 2,783 23 199	4,306 739 414 2,871 31 251
Guam P.R. V.I. Amer. Samoa C.N.M.I. N: Not notifiable.	4 U U U	- U U U Vailable.		68 U U U orted cases	488 U U U U	34 506 U U U		U U U U U

 TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending November 4, 2000, and November 6, 1999 (44th Week)

N: Not notifiable. U: Unavailable. -: No reported cases. \* Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

	Shigellosis*					ohilis	4111 Weer	-1
	NET			HLIS	(Primary &	Secondary)		rculosis
Reporting Area	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999
JNITED STATES	17,176	14,017	9,170	8,493	5,085	5,715	10,364	13,057
NEW ENGLAND Maine N.H.	343 10 6	765 5 16	329 12 8	736 14	65 1 2	53 - 1	346 12 16	360 16 12
/t. Mass. R.I. Conn.	4 236 26 61	6 656 23 59	220 28 61	4 636 20 62	41 4 17	3 31 2 16	4 215 27 72	2 200 35 95
MID. ATLANTIC Jpstate N.Y. N.Y. City N.J. Pa.	1,777 674 657 270 176	920 244 303 219 154	1,141 180 457 313 191	648 66 213 205 164	222 13 104 42 63	252 17 107 60 68	1,905 243 1,053 446 163	2,200 274 1,126 453 347
E.N. CENTRAL Dhio nd. II. Mich. Wis.	3,387 329 1,366 886 598 208	2,673 373 281 1,093 390 536	989 255 139 2 541 52	1,440 128 96 825 330 61	1,007 66 319 286 295 41	1,062 80 371 364 208 39	1,082 205 80 555 172 70	1,390 218 115 695 274 88
W.N. CENTRAL Minn. owa Mo. V. Dak. S. Dak. S. Dak. Nebr.	2,121 679 473 599 42 7 122	1,046 202 53 645 3 13 76	1,701 733 295 428 49 4 4 84	696 218 46 320 2 7 61	54 13 11 23 - 2	115 9 9 81 - -	400 128 32 164 2 16 21	440 168 39 161 6 17 16
Kans. S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	199 2,630 21 191 67 408 4 334 118 227 1,260	54 2,111 13 142 50 117 8 185 106 203 1,287	108 1,013 20 104 U 304 3 242 81 164 95	42 476 9 48 U 57 5 80 59 78 140	5 1,697 8 254 43 118 2 418 188 323 343	10 1,836 8 320 43 136 5 422 232 369 301	37 2,116 26 225 27 249 109 469 801	33 2,585 25 229 48 247 37 383 210 512 894
E.S. CENTRAL Ky. fenn. Ala. Miss.	984 410 327 72 175	1,055 218 610 107 120	479 90 334 49 6	621 142 411 58 10	759 73 454 107 125	981 88 550 188 155	758 100 280 257 121	887 154 311 261 161
N.S. CENTRAL Ark. _a. Okla. Tex.	1,937 178 134 109 1,516	2,275 73 183 501 1,518	2,436 44 152 35 2,205	1,007 25 109 150 723	692 86 187 108 311	904 65 265 164 410	870 149 74 113 534	1,666 145 190 152 1,179
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	1,083 7 44 5 241 132 466 73 115	957 9 24 3 171 121 487 56 86	619 2 169 67 304 77	662 12 135 89 359 60 6	214 1 1 11 20 175 1 5	202 1 2 11 181 2 4	417 14 10 2 68 36 175 41 71	436 13 12 3 61 51 182 34 80
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	2,914 408 155 2,307 8 36	2,215 104 78 2,004 3 26	463 339 94 3 27	2,207 101 74 2,001 3 28	375 55 6 313 - 1	310 63 6 237 1 3	2,470 207 25 2,040 84 114	3,093 218 93 2,576 49 157
Guam P.R. V.I. Amer. Samoa C.N.M.I.	23 U U U	15 129 U U U	U U U U U	U U U U U	128 U U U	- 134 U U U	238 U U U	56 172 U U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States	,
weeks ending November 4, 2000, and November 6, 1999 (44th Week)	

N: Not notifiable. U: Unavailable. -: No reported cases. \*Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

	and November 6, 1999 (44th Week)											
		uenzae,		epatitis (Vi		ре			1	les (Rubeo		
		isive	A	Cum	B	Cum	Indige		Impo		Total	
Reporting Area	Cum. 2000 <sup>†</sup>	Cum. 1999	Cum. 2000	Cum. 1999	Cum. 2000	Cum. 1999	2000	Cum. 2000	2000	Cum. 2000	Cum. 2000	Cum. 1999
UNITED STATES	1,012	1,008	10,142	13,912	5,641	5,883	1	55	-	18	73	86
NEW ENGLAND	83	83	302	295	84	135	-	2	-	4	6	11
Maine N.H.	1 12	7 17	19 18	11 16	5 15	1 15	-	- 2	-	- 1	- 3	- 1
Vt. Mass.	7 36	5 32	10 111	19 112	6 12	4 42	-	-	-	3	3	- 8
R.I. Conn.	4 23	5 17	22 122	21 116	18 28	33 40	-	-	-	-	-	- 2
MID. ATLANTIC	153	176	984	1,040	757	749		- 14		5	- 19	5
Upstate N.Y.	83	71	204	233	122	157	-	9	-	-	9	2
N.Y. City N.J.	32 29	54 46	307 154	343 133	385 57	227 115	-	5	-	4	9	3
Pa.	9	5	319	331	193	250	-	-	-	1	1	-
E.N. CENTRAL Ohio	132 47	167 54	1,215 234	2,552 567	609 93	620 81	-	8 2	-	-	8 2	4
Ind. III.	27 48	22 68	106 443	93 675	42 110	35 52	-	- 4	-	-	- 4	2 1
Mich.	7	17	419	1,149	363	423	-	2	-	-	2	1
Wis.	3	6	13	68	1	29	-	-	-	-	-	-
W.N. CENTRAL Minn.	61 35	63 40	669 177	751 75	500 35	279 48	1 -	3	-	1 1	4 1	1 1
lowa Mo.	1 16	2 8	64 295	124 462	33 370	37 163	-	2	-	-	2	-
N. Dak. S. Dak.	1	1 2	3	2	2	- 1	-	-	-	-	-	-
Nebr.	3	4	33	44	37	18	-	-	-	-	-	-
Kans.	4	6	96	35	22	12	1	1	-	-	1	-
S. ATLANTIC Del.	266	209	1,303	1,587 2	1,118	957 1	-	4	-	-	4	15 -
Md. D.C.	74	53 4	198 23	265 54	104 28	130 24	-	-	-	-	-	-
Va. W. Va.	35 9	17 7	136 53	149 35	140 13	77 22	-	2	-	-	2	13
N.C.	22	31	125	140	208	204	-	-	-	-	-	-
S.C. Ga.	15 63	5 55	72 257	41 424	21 197	61 145	-	-	-	-	-	-
Fla.	48	37	439	477	407	293	-	2	-	-	2	2
E.S. CENTRAL Ky.	42 12	53 6	350 43	351 64	390 64	404 40	-	-	-	-	-	2 2
Tenn. Ala.	19 10	29 15	122 52	140 50	186 48	197 79	-	-	-	-	-	-
Miss.	1	3	133	97	92	88	-	-	-	-	-	-
W.S. CENTRAL	56 2	55	1,597	2,680	631	1,013	-	-	-	-	-	12
Ark. La.	11	2 12	104 56	52 201	73 87	71 158	U -	-	U -	-	-	5
Okla. Tex.	41 2	37 4	232 1,205	445 1,982	137 334	127 657	-	-	-	-	-	-7
MOUNTAIN	92	94	846	1,093	464	495	-	11	-	1	12	1
Mont. Idaho	1 4	3 1	7 26	17 36	7 7	17 26	-	-	-	-	-	-
Wyo. Colo.	1 16	1 13	39 176	8 201	25 90	12 85	U	- 1	U	- 1	2	-
N. Mex.	19 37	18	63	44	93	155	U	-	U	-	-	-
Ariz. Utah	3/ 11	48 7	422 52	606 50	181 20	121 30	-	- 3	-	-	- 3	1 -
Nev.	3	3	61	131	41	49	-	7	-	-	7	-
PACIFIC Wash.	127 5	108 5	2,876 254	3,563 295	1,088 98	1,231 62	-	13 2	-	7 1	20 3	35 5
Oreg. Calif.	28 30	35 51	165 2,433	217 3,019	100 870	95 1,046	-	10	-	3	13	12 17
Alaska	41	9	11	11	9	<sup>.</sup> 15	-	1	-	-	1	-
Hawaii	23	8	13	21	11	13	-	-	-	3	3	1
Guam P.R.	4	2	198	1 279	217	2 207	-	-	-	-	-	1
V.I. Amer. Samoa	U U	U U	U U	U U	U U	U U	U U	U U	U U	U U	U U	U U
C.N.M.I.	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ

 TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending November 4, 2000, and November 6, 1999 (44th Week)

N: Not notifiable. U: Unavailable. - : No reported cases. \*For imported measles, cases include only those resulting from importation from other countries. \*Of 210 cases among children aged <5 years, serotype was reported for 85 and of those, 21 were type b.

Dises         Ourne         Curn.         Curn. <th< th=""><th></th><th>Mening</th><th>lococcal</th><th></th><th></th><th>J, 1999</th><th>(44())</th><th>week)</th><th></th><th></th><th></th><th></th></th<>		Mening	lococcal			J, 1999	(44())	week)				
Reporting Area         1990		Dise	ease		· · ·			_				
NEW ROLAND     118     99     -     4     8     19     1.22     680     -     12     7       N.H.     11     12     -     -     1     9     111     82     -     2     -       Mas.     89     55     -     1     4     8     906     473     -     8     7       Mas.     89     55     -     1     4     8     906     473     -     8     9       Conn.     17     15     -     2     -     -     42     23     -     -     4       N.Y.City     35     35     575     575     854     -     7     6       N.Y.City     36     365     -     30     1     -     44     48     66     -     1     2       Pa.     39     42     -     4     17     -     174     140     -     -     -       Pa.     39     42     -     7     144     -     290     180     -     -     -       Pa.     39     55     -     1     28     -     -     1     18        Pa.     5	<b>Reporting Area</b>			2000			2000	2000		2000		
Maine         8         5         -         -         -         -         41         - <td></td> <td>1,754</td> <td>2,046</td> <td>2</td> <td>278</td> <td>315</td> <td>109</td> <td></td> <td>5,421</td> <td>19</td> <td></td> <td></td>		1,754	2,046	2	278	315	109		5,421	19		
N.H.         11         12         -         -         1         9         111         82         -         2         -         -         -         -         1         2         209         62         -         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         <				-	4				680			7
	N.H.	11	12	-	-			111				-
Conn.         17         15         -         2         -         -         42         28         -         1         -           MD.ATLANTIC         162         200         -         10         99         5         525         854         -         2         18           N.Y.City         33         45         -         3         1         -         55         25         643         -         -         4           Pa.         33         46         -         3         1         -         55         25         643         -         -         4           Pa.         33         42         -         4         17         -         13         6044         490         -         1         2           Onio         71         126         -         16         10         7         88         85         -         1         1           Win.         23         33         -         -         1         128         315         188         1         1         50           Mo.         13         36         3         36         36         3         36	Mass.	68	56	-	1	4	8	903	475	-	8	
Upstate N.Y. 66 60 - 10 9 5 272 643 - 2 18 N.Y. City 33 53 - 4 11 - 35 23 - 7 4 Pa. 39 46 - 3 1 - 35 23 - 7 4 EN.CENTEAL 309 365 1 30 40 13 604 490 - 1 2 Ohio 79 124 - 7 14 - 290 186 - 1 1 Ind. 41 85 - 1 6 10 7 88 85 - 1 1 2 Mich. 29 33 - 7 4 4 - 783 86 - 1 1 1 Wis. 23 33 - 6 4 - 7 83 86 63 - 1 1 Wis. 23 33 - 7 4 4 - 72 103 - 7 - 1 Wis. 23 33 - 7 4 4 - 72 103 - 7 - 1 Wis. 23 33 - 7 7 7 2 4 6 63 1 1 3 Mich. 31 35 - 7 7 7 7 2 46 63 1 1 3 Mich. 29 47 - 1 88 12 31 512 393 1 3 1 27 Mino. 81 80 - 4 1 - 6 7 4 1 - 20 Mo. 81 80 - 4 1 - 6 7 4 1 - 1 2 N.Dak. 2 1 3 - 7 1 8 93 5 - 7 - 1 2 S.Dak. 5 11 1 - 4 - 2 6 7 - 1 2 S.Dak. 5 11 - 7 - 7 7 2 46 7 - 1 2 S.Dak. 5 11 - 7 - 7 7 7 - 4 68 7 3 7 1 18 92 - 3 Kates 8 1 80 - 4 1 - 8 7 2 8 7 - 1 - 9 Kates 8 1 80 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 Kates 8 1 80 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -				-					33 28			-
N.Y.City 33 63 - 4 11 - 44 48 - 7 6 P.J. 39 42 - 4 17 - 37 Pa. 39 42 - 4 77 - 714 - 290 186 3 Ohio 79 124 - 7 14 - 290 186 1 III. 72 96 - 6 10 1 88 88 - 1 1 III. 72 96 - 6 10 1 88 88 - 1 1 III. 72 96 - 6 10 1 88 88 - 1 1 III. 72 96 - 6 10 1 88 88 - 1 1 III. 72 96 - 6 10 1 88 88 - 1 3 VI.N.CENTRAL 184 206 - 18 12 31 512 983 1 3 127 Minn. 20 47 1 28 315 18 1 3 127 Minn. 20 47 1 28 315 18 1 3 1 27 Minn. 20 47 1 28 315 18 1 3 1 27 Minn. 20 47 1 28 315 18 1 1 5 N.Dak. 2 3 3 - 4 - 1 - 6 4 4 - 7 7 15 18 18 1 1 5 N.Dak. 2 3 3 - 4 - 1 - 6 4 4 - 7 1 Nebr. 7 10 - 4 - 2 7 7 5 - 1 Nebr. 7 10 - 4 - 2 8 7 - 1 90 S.ATLANTIC 277 344 - 41 45 8 437 371 18 92 36 S.ATLANTIC 277 344 - 41 45 8 437 371 18 92 36 N.C. 33 3 2 - 8 5 8 - 1 - 1 Md. 26 50 - 10 6 - 106 112 1 Md. 26 50 - 10 5 - 2 - 3 3 2 N.C. 33 4 8 5 5 - 1 N.C. 33 8 5 - 1 Md. 26 50 10 6 - 106 112 1 Md. 26 50 10 6 - 2 - 3 3 N.C. 33 Fia N.C. 33 N.C. 33 N.C. 33 N.C. 36 40 N.C. 37				-						-		
Pa.       39       42       -       4       17       -       174       140       -       -       3         Chio       79       124       -       7       14       13       604       490       -       1       2         Ind.       41       55       -       1       4       7       53       63       -       1       1         Wis.       23       33       -       6       10       1       88       85       -       1       1         Wis.       23       33       -       -       4       -       72       103       -       -       -       1       123       512       393       1       3       127         Minn.       20       47       -       -       1       28       73       -       1       20         Mo.       81       30       -       -       1       28       63       -       <	N.Y. City	33	53	-	4	11		44	48	-	7	6
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				-								
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$										-		
$\begin{array}{l c c c c c c c c c c c c c c c c c c c$		41	55					93	63	-	-	
Wis.         23         33         -         -         4         -         72         103         -         -         -           Wi.N.CENTRAL         154         206         -         18         12         31         512         393         1         3         127           Minn.         30         47         -         7         7         393         1         3         127           Mo         31         80         -         4         1         -         6         4         -         10           S.Dak.         5         11         -         -         -         7         7         5         -         -         -           S.ATLANTIC         277         7         44         -         45         8         437         371         18         92         2         -											1	1
$\begin{array}{l c c c c c c c c c c c c c c c c c c c$	Wis.		33	-					103	-		-
				-								
N.Dak.       2       3       -       -       -       -       -       -       -       7       0       -       -       -       7       7       1       90         Nabr.       7       10       -       4       -       -       28       7       -       1       90         S.Ak.       5       10       -       -       -       -       8       371       18       92       36         Del.       1       10       -       -       -       -       8       5       -       1       -         D.C.       -       3       -       -       2       -       3       - <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>				-								
Nebr.         7         10         -         4         -         -         28         7         -         1         90           S.ATLANTIC         277         344         -         41         45         8         437         371         18         92         35           Del.         1         10         -         -         -         -         8         5         -         1         -           Md.         26         50         -         10         6         -         106         112         - <td>N. Dak.</td> <td>2</td> <td>3</td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td>6</td> <td>4</td> <td></td> <td>-</td> <td>-</td>	N. Dak.	2	3	-	-	-		6	4		-	-
S.ATLANTIC       277       344       -       41       45       8       437       371       18       92       36         Del.       1       10       -       -       -       -       8       5       -       1       -         D.C.       -       3       -       -       2       -       3       -       -       -       -         W.A.       37       47       -       9       10       -       97       29       - <td< td=""><td>Nebr.</td><td>7</td><td>10</td><td>-</td><td>4</td><td>-</td><td>-</td><td>28</td><td>7</td><td>-</td><td>1</td><td></td></td<>	Nebr.	7	10	-	4	-	-	28	7	-	1	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$				-								
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Del.	1	10	-	-	-	-	8	5	-	1	-
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	D.C.	-	3	-	-	2		3	-		-	-
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$				-					29 3		-	-
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$				-								34
E.S. CENTRAL       120       142       -       7       13       -       98       86       -       5       2         Ky,       26       28       -       1       -       -       49       26       -       1       -         Tenn.       51       58       -       2       10       -       18       21       -       3       2         Miss.       12       22       -       2       3       -       1       3       -       -       -       30       36       -       1       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       -       1       -       14       -       -       -       10       -       12       9       -       1       -       -       -       10       -       -       110       -       -       -       110       -       -       -       -       -       110       -       -       -       -       -       -       -       -       -       -       -       -       - </td <td>Ga.</td> <td>43</td> <td>58</td> <td>-</td> <td>2</td> <td>4</td> <td>1</td> <td>37</td> <td>38</td> <td></td> <td>-</td> <td>-</td>	Ga.	43	58	-	2	4	1	37	38		-	-
Ky, Tenn.2628-14926-1-Tenn.5158-23036-1-Miss.1222-23-13232Miss.1222-23-13W.S. CENTRAL117191-2439-286192-514Ark.1331U2-U3224U-5La.3560-410-129-1-Tex.4371-1828-223125-48MOUNTAIN124126-202516683673-216Mont.44-1352Vyo4U2-U62UMyo4U2-U62UVyo4U2-U62UNex.814U1NU80109UNex.814U<				-								2
Ala.3134-210-1821-32Miss.1222-23-13W.S. CENTRAL117191-2439-286192-514Ark.1331U2-U3224U-5La.3560-410-129-1-Okla.26291-19341Tex.4371-1828-223125-48MOUNTAIN124126-202516683673-216Mont.44-1352Wyo4U2-U62UColo.3333-1613402257-111Ariz,6241-48-7097-113Vah,714-543215611Vah,7657179901,682-71133038<	Ky.	26	28	-	1	-	-	49	26	-	1	-
W.S. CENTRAL117191-2439-286192-514Ark.1331U2-U3224U-5La.3560-410-129-1-Okla.26291-19341Tex.4371-1828-223125-48MOUNTAIN124126-202516683673-216Mont.44-1352Woo4U2-U62UColo.3333-1613402257-111N.Mex.814U1NU80109UAriz.6241-48-7097-113Utah714-5432156-11Nev.37-65-128-11PACIFIC375374111395179901,682-175522	Ala.	31	34	-	2			18	21		3	2
Ark.1331U2-U3224U-5La.3560-410-129-1-Okla.26291-19341Tex.4371-1828-223125-48MOUNTAIN124126-202516683673-216Mont.44-1352Idaho792-57142Colo.3333-1613402257-111N.Mex.814U1NU80109UAriz.6241-48-7097-113Utah714-5432156624-7-Nev.37-65-11151Vash.5461-10212356624-7 </td <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td>- 14</td>				-				-				- 14
Okla.       26       29       -       -       1       -       19       34       -       -       1         Tex.       43       71       -       18       28       -       223       125       -       4       8         MOUNTAIN       124       126       -       20       25       16       683       673       -       2       16         Mont.       4       4       -       1       -       -       35       2       -       1       16       13       402       257       -       1       1       13       0       10       113       402       257       -       1       1       13       13       13	Ark.	13	31		2	-		32	24		-	5
MOUNTAIN       124       126       -       20       25       16       683       673       -       2       16         Mont.       4       4       -       1       -       -       35       2       -	Okla.	26	29		-	1	-	19	34	-	-	1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$				-						-		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Mont.	4	4	-	1	-	-	35	2	-		-
Ariz.       62       41       -       4       8       -       70       97       -       1       13         Utah       7       14       -       5       4       3       21       56       -       -       1         Nev.       3       7       -       6       5       -       12       8       -       -       1         PACIFIC       375       374       1       113       95       17       990       1,682       -       17       5         Wash.       54       61       -       10       2       12       356       624       -       7       -         Oreg.       62       67       N       N       N       -       111       51       -       -       -         Calif.       243       233       1       82       78       5       473       964       -       10       5         Alaska       8       7       -       7       2       -       20       5       -       -       -         Guam       -       1       -       -       3       -       2       -	Wyo.	-	4		2	-	U	6	2		-	-
Utah       7       14       -       5       4       3       21       56       -       -       1         Nev.       3       7       -       6       5       -       12       8       -       -       1         PACIFIC       375       374       1       113       95       17       990       1,682       -       17       5         Wash.       54       61       -       10       2       12       356       624       -       7       -         Oreg.       62       67       N       N       -       111       51       -       -       -       -       Calif.       243       233       1       82       78       5       473       964       -       10       5         Alaska       8       7       -       7       2       -       20       5       -       -       -         Guam       -       1       -       -       3       -       -       2       -       2       -       -       -       -       -       -       -       -       -       -       -       -       - <td></td> <td>33 8</td> <td>33 14</td> <td></td> <td>1</td> <td>N</td> <td>U</td> <td>80</td> <td>109</td> <td></td> <td>-</td> <td>-</td>		33 8	33 14		1	N	U	80	109		-	-
Nev.       3       7       -       6       5       -       12       8       -       -       1         PACIFIC       375       374       1       113       95       17       990       1,682       -       17       5         Wash.       54       61       -       10       2       12       356       624       -       7       -         Oreg.       62       67       N       N       -       111       51       -       -       -         Calif.       243       233       1       82       78       5       473       964       -       10       5         Alaska       8       7       -       7       2       -       20       5       -       -       -         Hawaii       8       6       -       14       13       -       30       38       - <td></td> <td>62 7</td> <td>41 14</td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td>97 56</td> <td>-</td> <td>1</td> <td></td>		62 7	41 14	-					97 56	-	1	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Nev.	3	7	-	6	5	-	12	8	-	-	
Oreg.         62         67         N         N         N         -         111         51         -         -         -         Calif.         243         233         1         82         78         5         473         964         -         10         5           Alaska         8         7         -         7         2         -         20         5         -         -         -           Hawaii         8         6         -         14         13         -         30         38         -		54	61	-	10	2			624	-		5
Alaska       8       7       -       7       2       -       20       5       -       -       -         Hawaii       8       6       -       14       13       -       30       38       -			67		N		-	111	51	-	- 10	- 5
Guam       -       1       -       -       3       -       -       2       -	Alaska	8	7	-	7	2	-	20	5	-	-	-
P.R.         9         11         -         -         -         5         22         - <td></td> <td>-</td> <td></td> <td>-</td> <td>-</td> <td></td> <td>-</td> <td>-</td> <td></td> <td>-</td> <td>-</td> <td>-</td>		-		-	-		-	-		-	-	-
Amer. Samoa U U U U U U U U U U U	P.R.	9 U	11	- 11		-		5	22 11		- U	- 11
	Amer. Samoa	U	U	U	U	U	U	U	U	U	U	U

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable
by vaccination, United States, weeks ending November 4, 2000,
and November 6, 1999 (44th Week)

N: Not notifiable. U: Unavailable.

- : No reported cases.

	ļ	All Cau	ises, By	Age (Y	ears)		, P&I <sup>†</sup>			All Cau	ises, By	/ Age (Y	'ears)		P&I⁺
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn Cambridge, Mass Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Ma New Haven, Conn Providence, R.I. Somerville, Mass Springfield, Mass Waterbury, Conn. Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§	492 139 . 33 . 15 . 56 18 . 27 56 18 . 8 . 24 . 28 . U . 7 . 44	346 846 25 12 235 12 16 21 19 U 7 34 19 39 1,619 35 20 76 12 24 39	34 6 2 1 3 5 2 2 8 U 5 3 12 432 20 6 3	38 16 1 - 4 1 1 U - 4 4 4 4 167 3 1 9 2 2 2 1	84 11 - - - - - - - - - - - - - - - - - -	7 1 - - - - - - - - - - - - - - - - - -	42 13 2 2 1 2 1 2 1 2 2 1 2 2 1 2 2 4 3 8 12 8 12 8 12 8 12 3	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, F Tampa, Fla. Washington, D.C Wilmington, Del E.S. CENTRAL Birmingham, Ala Chattanooga, Te Knoxville, Tenn. Lexington, Ky. Memphis, Tenn. Mobile, Ala. Montgomery, Al	1,142 149 133 94 . 146 85 51a. 76 55 51a. 76 1. U 812 a. 138 snn. 69 64 . 198 88 . 88	86 83 48 90 45 30 45 111 80 550 856 43 43 134 134 550 856 43 43 134 550 856 43 43 43 550 856 43 43 43 550 856 43 43 43 550 856 43 550 856 43 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 455 550 856 550 856 550 856 1356 1356 1356 1356 1356 1356 1356 13	242 41 35 22 31 17 14 12 3 0 37 20 0 156 29 10 14 12 42 19 7 23	109 16 13 16 16 5 14 5 4 15 6 U 64 11 2 5 7 14 3 3 19	29 5 2 3 5 2 3 5 2 3 1 1 2 1 4 U 21 5 1 3 1 2 3 1 2 3 5 2 3 2 3	299 1 5 2 2 2 4 1 - 2 5 7 U 19 3 - 1 1 5 2 2 - 7 - - - - - - - - - - - - -	73 3 19 5 13 4 3 2 7 5 9 3 U 55 5 5 3 6 15 3 5 13
Jersey City, N.J. New York City, N.J. Newark, N.J. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	35 Y. 1,121 90 26 373 69 27 129	32 790 35 270 44 21 100 7 22 54 14 18 U	10 219 23 7 65 16 4 22 4 2 10 3	1 83 22 28 4 1 3 1 1 2 - 1 U	16 3 1 8 1 - 1 - - U	2 12 7 2 4 1 3 - 2 - 2 - U	5 - 50 4 1 21 4 2 14 2 3 7 - 4 U	W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi, T Dallas, Tex. El Paso, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La San Antonio, Te Shreveport, La. Tulsa, Okla.	1,462 85 . 69 Fex. 53 207 94 82 380 65 . U	935 57 41 33 123 64 60 224 35 U 138 50 110	300 16 17 12 46 19 15 79 17 U 44 13 22	126 4 8 4 23 9 5 41 7 U 15 6 4	60 6 1 2 7 1 2 9 3 U 3 4 4	41 22 28 12 73 U 734	102 2 4 3 13 2 8 29 6 U 22 2 11
E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, Ill. Cincinnati, Ohio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Gary, Ind. Grand Rapids, Mi Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, Ill. Rockford, Ill. South Bend, Ind. Toledo, Ohio Youngstown, Ohi W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans Kansas City, Kans Kansas City, Mo. Lincoln, Nebr. Minneapolis, Min Omaha, Nebr. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	166 54 116 35 55 113 0 66 809 61 327 27 85 58	$\begin{array}{c} 1,149\\ 38\\ 315\\ 866\\ 1077\\ 0\\ 3350\\ 1142\\ 755\\ 342\\ 859\\ 0050\\ 2616\\ 0\\ 846\\ 666\\ 57\\ 146\\ 666657\\ 1466\\ 1466\\ 66657\\ 1466\\ 14$	5 7 8 13 27 33 18 U 7 9 4 4 33 7 26 7 5 11 17 4 12 9 7 3 7 16 4 25 17 18 121	106 7 1 27 1 11 14 5 U 1 8 2 - 9 3 5 1 4 1 5 1 4 8 2 3 4 3 9 7 12 3 4 3 9 7 12 3 4	522 - 1822320 - 3216151 - 121 221111431632 -	41	84418772202286546152 82215225-53	MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, U Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Cali Dasadena, Calif. Portland, Oreg. Sacramento, Cal San Diego, Calif San Francisco, C San Jose, Calif. Santa Cruz, Calif Santa Cruz, Calif Seattle, Wash. Tacoma, Wash. TOTAL	35 olo. 68 109 239 28 163 27 tah 99 137 2,081 37 2,081 16 86 40 11 127 117 127 117 127 115 128 112 112	20 65 91 1,439 12 62 31 50 50 487 14 75 109 146 82 122 25 72 44 55	29 40 5 29 9 21	72 U 16 14 19 2 3 10 141 - 6 2 4 4 1 21 0 111 9 3 7 5 5 871	30 U - 2 4 7 - 9 1 4 3 51 1 7 8 1 9 1 5 2 3 - 2 - 2 3 12	27 U 1 4 3 1 8 - 7 3 4 1 1 1 - 2 - 0 - 4 4 6 4 4 - 2 3 - 253	54 U 3 - 5 15 3 13 3 10 2 15 6 3 - 11 8 6 3 7 7 7 18 11 19 2 2 5 9 738

# TABLE IV. Deaths in 122 U.S. cities,\* week ending<br/>November 4, 2000 (44th Week)

U: Unavailable. -:No reported cases. \*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. \*Pneumonia and influenza. \*Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. \*Total includes unknown ages.

Vol. 49 / No. 44

1019

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov.* The body content should read *SUBscribe mmwr-toc.* Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at *ftp://ftp.cdc.gov/pub/Publications/mmwr.* To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.	Acting Director, Epidemiology Program Office Barbara R. Holloway, M.P.H.	Writers-Editors, <i>MMWR</i> (Weekly) Jill Crane David C. Johnson							
Deputy Director for Science and Public Health, Centers for Disease Control and Prevention David W. Fleming, M.D.	Editor, <i>MMWR</i> Series John W. Ward, M.D. Acting Managing Editor, <i>MMWR</i> (Weekly) Teresa F. Rutledge	Desktop Publishing Lynda G. Cupell Morie M. Higgins							
☆U.S. Government Printing Office: 2001-633-173/48010 Region IV									